MedTrace Logo

Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

NCT07168876 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3200

Last updated 2025-09-11

No results posted yet for this study

Summary

CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.

Conditions

  • Colorectal Cancer (CRC)

Sponsors & Collaborators

  • Epiliquid Holding, Inc

    lead INDUSTRY

Principal Investigators

  • Emanuel Campoy, PhD · CONICET-National Scientific and Technical Research Council

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-04
Primary Completion
2025-12-31
Completion
2028-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168876 on ClinicalTrials.gov